retatrutide vs tirzepatide

retatrutide (S-tier) vs tirzepatide (S-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

retatrutide — tier S

the most potent weight loss drug ever tested. 24.2% in phase 2, then 28.3% in TRIUMPH-1 phase 3, 30.3% at two years. not approved yet.

the triple agonist with the highest weight-loss number ever recorded in a phase 3 obesity trial. not FDA-approved yet.

28.3% TRIUMPH-1 phase 3 · half-life ~6 days · weight loss

tirzepatide — tier S

mounjaro and zepbound. GLP-1 plus GIP dual agonist. beats semaglutide head-to-head on weight loss.

the dual GLP-1/GIP agonist that beat semaglutide head-to-head. mounjaro for diabetes, zepbound for obesity, same molecule.

22.5% SURMOUNT-1 wt loss · half-life ~5 days · weight loss

at a glance

• retatrutide: tier S · 28.3% TRIUMPH-1 phase 3
• tirzepatide: tier S · 22.5% SURMOUNT-1 wt loss

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.